HomeCompareADAPY vs SBUX

ADAPY vs SBUX: Dividend Comparison 2026

ADAPY yields 17391.30% · SBUX yields 2.84%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ADAPY wins by $13116176655014998016.00M in total portfolio value
10 years
ADAPY
ADAPY
● Live price
17391.30%
Share price
$0.01
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$13116176655014998016.00M
Annual income
$12,969,477,336,575,606,000,000,000.00
Full ADAPY calculator →
SBUX
SBUX
● Live price
2.84%
Share price
$86.72
Annual div
$2.46
5Y div CAGR
48.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$167.0K
Annual income
$71,136.45
Full SBUX calculator →

Portfolio growth — ADAPY vs SBUX

📍 ADAPY pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodADAPYSBUX
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ADAPY + SBUX cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ADAPY pays
SBUX pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ADAPY
Annual income on $10K today (after 15% tax)
$1,478,260.87/yr
After 10yr DRIP, annual income (after tax)
$11,024,055,736,089,265,000,000,000.00/yr
SBUX
Annual income on $10K today (after 15% tax)
$241.12/yr
After 10yr DRIP, annual income (after tax)
$60,465.98/yr
At 15% tax rate, ADAPY beats the other by $11,024,055,736,089,265,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ADAPY + SBUX for your $10,000?

ADAPY: 50%SBUX: 50%
100% SBUX50/50100% ADAPY
Portfolio after 10yr
$6558088327507499008.00M
Annual income
$6,484,738,668,287,803,000,000,000.00/yr
Blended yield
98.88%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on SBUX right now

ADAPY
Analyst Ratings
9
Buy
4
Hold
3
Sell
Consensus: Buy
Price Target
$2.83
+24508.7% upside vs current
Range: $1.00 — $4.00
Altman Z
-15.9
Piotroski
0/9
SBUX
Analyst Ratings
28
Buy
27
Hold
3
Sell
Consensus: Buy
Price Target
$104.00
+19.9% upside vs current
Range: $90.00 — $120.00
Altman Z
2.6
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ADAPY buys
0
SBUX buys
0
No recent congressional trades found for ADAPY or SBUX in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricADAPYSBUX
Forward yield17391.30%2.84%
Annual dividend / share$2.00$2.46
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%48.3%
Portfolio after 10y$13116176655014998016.00M$167.0K
Annual income after 10y$12,969,477,336,575,606,000,000,000.00$71,136.45
Total dividends collected$13106484814212466688.00M$136.4K
Payment frequencyquarterlyquarterly
SectorStockConsumer Discretionary
Analyst consensusBuyBuy
Analyst price target$2.83$104.00

Year-by-year: ADAPY vs SBUX ($10,000, DRIP)

YearADAPY PortfolioADAPY Income/yrSBUX PortfolioSBUX Income/yrGap
1← crossover$1,749,830$1,739,130.43$11,121$420.68+$1.74MADAPY
2$286,281,979$284,409,660.27$12,548$648.40+$286.27MADAPY
3$43,793,237,807$43,486,916,089.97$14,440$1,013.98+$43793.22MADAPY
4$6,263,959,119,982$6,217,100,355,528.48$17,068$1,617.30+$6263959.10MADAPY
5$837,788,422,535,934$831,085,986,277,552.80$20,912$2,649.52+$837788422.52MADAPY
6$104,780,184,325,077,740$103,883,750,712,964,290.00$26,875$4,499.29+$104780184325.05MADAPY
7$12,254,629,759,849,812,000$12,142,514,962,621,979,000.00$36,771$8,014.12+$12254629759849.78MADAPY
8$1,340,341,587,727,856,400,000$1,327,229,133,884,817,100,000.00$54,542$15,197.11+$1340341587727856.50MADAPY
9$137,102,166,765,785,570,000,000$135,668,001,266,916,780,000,000.00$89,602$31,242.49+$137102166765785568.00MADAPY
10$13,116,176,655,014,997,000,000,000$12,969,477,336,575,606,000,000,000.00$167,011$71,136.45+$13116176655014998016.00MADAPY

ADAPY vs SBUX: Complete Analysis 2026

ADAPYStock

Adaptimmune Therapeutics plc, a commercial-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops TECELRA ((famitresgene autoleucel or afami-cel), a genetically modified autologous T-cell immunotherapy for the treatment of adults with unresectable or metastatic synovial sarcoma; Lete-cel for the treatment synovial sarcoma and myxoid liposarcoma; and ADP-5701, which is in Phase 1 clinical trial for the treatment of head and neck cancer. The company also focuses on the development of T-cell therapies directed to PRAME (ADP-600) and CD70 (ADP-520). It has strategic collaboration with Galapagos to clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel produced on Galapagos' decentralized manufacturing platform (ADP-5701) in patients with head and neck cancer; collaboration and license agreement with Noile-Immune Biotech, Inc. and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.

Full ADAPY Calculator →

SBUXConsumer Discretionary

Starbucks Corporation, together with its subsidiaries, operates as a roaster, marketer, and retailer of specialty coffee worldwide. The company operates through three segments: North America, International, and Channel Development. Its stores offer coffee and tea beverages, roasted whole beans and ground coffees, single serve products, and ready-to-drink beverages; and various food products, such as pastries, breakfast sandwiches, and lunch items. The company also licenses its trademarks through licensed stores, and grocery and foodservice accounts. The company offers its products under the Starbucks, Teavana, Seattle's Best Coffee, Evolution Fresh, Ethos, Starbucks Reserve, and Princi brands. As of October 3, 2021, it operated 16,826 company-operated and licensed stores in North America; and 17,007 company-operated and licensed stores internationally. The company was founded in 1971 and is based in Seattle, Washington.

Full SBUX Calculator →
📬

Get this ADAPY vs SBUX comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ADAPY vs SCHDADAPY vs JEPIADAPY vs OADAPY vs KOADAPY vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.